Product Information
PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE is a generic product labeled by Prasco Laboratories, priced at $2.8472 per EA under NDC 66993078330. Its NADAC has been published 55 times since Sep 17, 2025.
FDA first approved this application on Jul 17, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
15; 92 mg/1; mg/1
Manufacturer
Prasco LaboratoriesNDC
66993078330
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDE; TOPIRAMATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022580FDA Approved
7/17/2012
TE Code
AB
On Market Since
6/1/2025
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE has been published 55 times since Sep 17, 2025, and over the history we have for it it has declined 9.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.8472 per EA |
|---|---|
| All-time high | $3.7531 (Mar 11, 2026) |
| All-time low | $2.8472 (Sep 23, 2026) |
| 52-week high | $3.7531 |
| 52-week low | $2.8472 |
| Median price | $3.4119 |
| Average price | $3.4292 |
| Largest weekly change | -10.6% (Sep 23, 2026) |
| Weeks tracked | 55 |
| Tracking since | Sep 17, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Prasco Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
phentermine and topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE, manufactured by Prasco Laboratories, is $2.8472 per EA (NDC 66993078330), effective Sep 30, 2026.
How has the price of PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE has declined 9.4%. It has been tracked across 55 weekly CMS publications since Sep 17, 2025.
What are the highest and lowest recorded NADAC prices for PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE?
Since Sep 17, 2025, the NADAC for PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE has ranged from a low of $2.8472 (Sep 23, 2026) to a high of $3.7531 (Mar 11, 2026), with a median of $3.4119 per EA.
Are there cheaper alternatives to PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE?
PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE (NDC 66993078330) is labeled by Prasco Laboratories, and CMS classifies it as a generic product.